These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29481630)

  • 1. Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer.
    Cortes J; Perez-Garcia J; Levy C; Gómez Pardo P; Bourgeois H; Spazzapan S; Martínez-Jañez N; Chao TC; Espié M; Nabholtz JM; Gonzàlez Farré X; Beliakouski V; Román García J; Holgado E; Campone M
    Ann Oncol; 2018 Apr; 29(4):881-887. PubMed ID: 29481630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.
    Martin M; Campone M; Bondarenko I; Sakaeva D; Krishnamurthy S; Roman L; Lebedeva L; Vedovato JC; Aapro M
    Ann Oncol; 2018 May; 29(5):1195-1202. PubMed ID: 29447329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy.
    Fumoleau P; Cortés-Funes H; Taleb AB; Chan S; Campone M; Pouget JC; Tubiana-Hulin M; Slabber CF; Caroff-Paraïso I; Alberts AS; Ben Ayed F
    Am J Clin Oncol; 2009 Aug; 32(4):375-80. PubMed ID: 19487917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer.
    Palmieri C; Alifrangis C; Shipway D; Tat T; Watson V; Mackie D; Emson M; Coombes RC
    Oncologist; 2012; 17(11):1429-e47. PubMed ID: 23002126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
    Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
    Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vinflunine.
    Frampton JE; Moen MD
    Drugs; 2010 Jul; 70(10):1283-93. PubMed ID: 20568834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).
    Bellmunt J; Kerst JM; Vázquez F; Morales-Barrera R; Grande E; Medina A; González Graguera MB; Rubio G; Anido U; Fernández Calvo O; González-Billalabeitia E; Van den Eertwegh AJM; Pujol E; Perez-Gracia JL; González Larriba JL; Collado R; Los M; Maciá S; De Wit R;
    Ann Oncol; 2017 Jul; 28(7):1517-1522. PubMed ID: 28419193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.
    Perez EA; Awada A; O'Shaughnessy J; Rugo HS; Twelves C; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; Cortes J
    Lancet Oncol; 2015 Nov; 16(15):1556-1568. PubMed ID: 26482278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy.
    Campone M; Cortes-Funes H; Vorobiof D; Martin M; Slabber CF; Ciruelos E; Bourbouloux E; Mendiola C; Delgado FM; Colin C; Aslanis V; Fumoleau P
    Br J Cancer; 2006 Nov; 95(9):1161-6. PubMed ID: 17031408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen.
    Culine S; Theodore C; De Santis M; Bui B; Demkow T; Lorenz J; Rolland F; Delgado FM; Longerey B; James N
    Br J Cancer; 2006 May; 94(10):1395-401. PubMed ID: 16622447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.
    Norris B; Pritchard KI; James K; Myles J; Bennett K; Marlin S; Skillings J; Findlay B; Vandenberg T; Goss P; Latreille J; Rudinskas L; Lofters W; Trudeau M; Osoba D; Rodgers A
    J Clin Oncol; 2000 Jun; 18(12):2385-94. PubMed ID: 10856098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of vinflunine in relapsed small cell lung cancer.
    Spigel DR; Hainsworth JD; Lane CM; Clark B; Burris HA; Greco FA
    J Thorac Oncol; 2010 Jun; 5(6):874-8. PubMed ID: 20521355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer.
    Yardley DA; McCleod M; Schreiber F; Murphy P; Patton J; Thompson DS; Shastry M; Rubin M; Melnik M; Burris HA; Hainsworth JD
    Cancer Invest; 2010 Nov; 28(9):925-31. PubMed ID: 20690806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
    Harbeck N; Huang CS; Hurvitz S; Yeh DC; Shao Z; Im SA; Jung KH; Shen K; Ro J; Jassem J; Zhang Q; Im YH; Wojtukiewicz M; Sun Q; Chen SC; Goeldner RG; Uttenreuther-Fischer M; Xu B; Piccart-Gebhart M;
    Lancet Oncol; 2016 Mar; 17(3):357-366. PubMed ID: 26822398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of intravenous vinflunine after failure of first-line vinorelbine based regimen for advanced breast cancer.
    Blasinska-Morawiec M; Tubiana-Mathieu N; Fougeray R; Pinel MC; Bougnoux P
    Breast; 2013 Feb; 22(1):58-63. PubMed ID: 23195794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer.
    Mansour M; Mourad C
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):429-35. PubMed ID: 23801283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vinflunine.
    Prescrire Int; 2011 Jan; 20(112):11-3. PubMed ID: 21462785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
    Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study.
    Vaughn DJ; Srinivas S; Stadler WM; Pili R; Petrylak D; Sternberg CN; Smith DC; Ringuette S; de Wit E; Pautret V; George C
    Cancer; 2009 Sep; 115(18):4110-7. PubMed ID: 19536904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.